An experimental drug has delivered what researchers are calling one of the most significant advances in pancreatic cancer treatment in decades. In a large international clinical trial, the once-daily pill daraxonrasib nearly doubled survival time for patients with advanced pancreatic cancer compared with standard chemotherapy, offering new hope against one of the deadliest forms of cancer.
Pancreatic cancer remains one of the most difficult cancers to treat, largely because it is often diagnosed after it has already spread. Patients with advanced disease typically face limited treatment options and poor survival rates.
The new Phase III trial involved approximately 500 patients whose cancer had progressed after an initial round of treatment. Researchers found that patients receiving daraxonrasib lived a median of 13.2 months, compared with 6.7 months for those receiving standard chemotherapy. The drug also reduced the risk of death by about 60%.
Daraxonrasib works by targeting KRAS, a gene mutation found in more than 90% of pancreatic cancers. For decades, KRAS was considered one of the most difficult targets in cancer research because of its complex molecular structure.
Researchers at Revolution Medicines developed the drug using a novel mechanism that blocks cancer-promoting KRAS signaling. Scientists say the success of the trial demonstrates that directly targeting KRAS can significantly improve outcomes for patients.
Beyond extending survival, the treatment appeared to improve patients' quality of life. According to researchers, some participants experienced enough symptom relief to return to activities they had previously abandoned because of their illness. Tumor growth was halted or reversed in nearly one-third of patients receiving the drug, compared with about 10% of those treated with chemotherapy.
The most common side effect was a skin rash, reported in many patients. However, doctors described the side effects as generally manageable and often less debilitating than those associated with conventional chemotherapy.
Cancer specialists have reacted enthusiastically to the findings. Researchers presenting the results at the annual meeting of the American Society of Clinical Oncology described the trial as a potential turning point in pancreatic cancer treatment. Some experts called it the most important advance in the field in decades.
Despite the excitement, specialists caution that the drug is not a cure. Most patients eventually develop resistance to treatment, and researchers are already investigating combination therapies that could prolong the benefits even further.
The findings were presented at ASCO's annual conference and published alongside peer-reviewed research. Regulators in the United States have already granted expanded access to eligible patients while the drug undergoes formal review. Full approval could come later this year if the evidence continues to support its safety and effectiveness.
Researchers are also exploring whether daraxonrasib could benefit patients with other KRAS-driven cancers, including lung and colorectal cancer. If successful, the drug's impact could extend far beyond pancreatic cancer alone
Read the full article here.